A citation-based method for searching scientific literature


List of co-cited articles
518 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Matthew D Hellmann, Jamie E Chaft, William N William, Valerie Rusch, Katherine M W Pisters, Neda Kalhor, Apar Pataer, William D Travis, Stephen G Swisher, Mark G Kris. Lancet Oncol 2014
262
43

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Catherine A Shu, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Claud M Grigg, Aliyah Pabani, Robert F Garofano, Mark B Stoopler, Simon K Cheng, Abby White,[...]. Lancet Oncol 2020
229
41

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño,[...]. Lancet Oncol 2020
231
41

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Jean-Pierre Pignon, Hélène Tribodet, Giorgio V Scagliotti, Jean-Yves Douillard, Frances A Shepherd, Richard J Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour,[...]. J Clin Oncol 2008
40

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
959
39

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome, Alan Mitchell, Vanessa Bolejack. J Thorac Oncol 2016
27

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Apar Pataer, Neda Kalhor, Arlene M Correa, Maria Gabriela Raso, Jeremy J Erasmus, Edward S Kim, Carmen Behrens, J Jack Lee, Jack A Roth, David J Stewart,[...]. J Thorac Oncol 2012
199
26

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
498
24

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Shugeng Gao, Ning Li, Shunyu Gao, Qi Xue, Jianming Ying, Shuhang Wang, Xiuli Tao, Jun Zhao, Yousheng Mao, Bing Wang,[...]. J Thorac Oncol 2020
156
24

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna C B Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben,[...]. Nat Med 2021
152
23

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Enriqueta Felip, Rafael Rosell, José Antonio Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, José Luis González-Larriba, Antonio Torres,[...]. J Clin Oncol 2010
227
20

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng,[...]. J Clin Oncol 2019
115
18

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
William D Travis, Sanja Dacic, Ignacio Wistuba, Lynette Sholl, Prasad Adusumilli, Lukas Bubendorf, Paul Bunn, Tina Cascone, Jamie Chaft, Gang Chen,[...]. J Thorac Oncol 2020
104
17

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
T R Cottrell, E D Thompson, P M Forde, J E Stein, A S Duffield, V Anagnostou, N Rekhtman, R A Anders, J D Cuda, P B Illei,[...]. Ann Oncol 2018
179
16

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Sacha I Rothschild, Alfred Zippelius, Eric I Eboulet, Spasenija Savic Prince, Daniel Betticher, Adrienne Bettini, Martin Früh, Markus Joerger, Didier Lardinois, Hans Gelpke,[...]. J Clin Oncol 2021
77
19

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu,[...]. Lancet 2021
173
15

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad, Enriqueta Felip, Stephen R Broderick, Julie R Brahmer, Scott J Swanson,[...]. N Engl J Med 2022
106
15

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
14

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Matthew J Bott, Stephen C Yang, Bernard J Park, Prasad S Adusumilli, Valerie W Rusch, James M Isbell, Robert J Downey, Julie R Brahmer, Richard Battafarano, Errol Bush,[...]. J Thorac Cardiovasc Surg 2019
135
14

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.
R Arriagada, A Auperin, S Burdett, J P Higgins, D H Johnson, T Le Chevalier, C Le Pechoux, M K B Parmar, J P Pignon, R L Souhami,[...]. Lancet 2010
431
13

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Jing Liu, Stephen J Blake, Michelle C R Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S O'Donnell, Stacey Allen, Mark J Smyth,[...]. Cancer Discov 2016
399
13

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Yang Qu, Katsura Emoto, Takashi Eguchi, Rania G Aly, Hua Zheng, Jamie E Chaft, Kay See Tan, David R Jones, Mark G Kris, Prasad S Adusumilli,[...]. J Thorac Oncol 2019
52
25

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
13

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
Katherine M W Pisters, Eric Vallières, John J Crowley, Wilbur A Franklin, Paul A Bunn, Robert J Ginsberg, Joe B Putnam, Kari Chansky, David Gandara. J Clin Oncol 2010
154
12

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Miklos Pless, Roger Stupp, Hans-Beat Ris, Rolf A Stahel, Walter Weder, Sandra Thierstein, Marie-Aline Gerard, Alexandros Xyrafas, Martin Früh, Richard Cathomas,[...]. Lancet 2015
199
12

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Annikka Weissferdt, Apar Pataer, Ara A Vaporciyan, Arlene M Correa, Boris Sepesi, Cesar A Moran, Ignacio I Wistuba, Jack A Roth, Jitesh Baban Shewale, John V Heymach,[...]. Clin Lung Cancer 2020
45
26

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu,[...]. Lancet Oncol 2018
312
11

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
Jamie E Chaft, Valerie Rusch, Michelle S Ginsberg, Paul K Paik, David J Finley, Mark G Kris, Katharine A R Price, Christopher G Azzoli, Matthew G Fury, Gregory J Riely,[...]. J Thorac Oncol 2013
84
13

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
11

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2018
11

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
11

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Karen Kelly, Nasser K Altorki, Wilfried E E Eberhardt, Mary E R O'Brien, David R Spigel, Lucio Crinò, Chun-Ming Tsai, Joo-Hang Kim, Eun Kyung Cho, Philip C Hoffman,[...]. J Clin Oncol 2015
282
10

Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William N William, Apar Pataer, Neda Kalhor, Arlene M Correa, David C Rice, Ignacio I Wistuba, John Heymach, J Jack Lee, Edward S Kim, Reginald Munden,[...]. J Thorac Oncol 2013
77
12

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
10


Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Rodrigo Arriagada, Bengt Bergman, Ariane Dunant, Thierry Le Chevalier, Jean-Pierre Pignon, Johan Vansteenkiste. N Engl J Med 2004
10

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Kathy S Albain, R Suzanne Swann, Valerie W Rusch, Andrew T Turrisi, Frances A Shepherd, Colum Smith, Yuhchyau Chen, Robert B Livingston, Richard H Feins, David R Gandara,[...]. Lancet 2009
963
10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
9

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
9

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
9

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
9

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
9

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Gideon M Blumenthal, Paul A Bunn, Jamie E Chaft, Caroline E McCoach, Edith A Perez, Giorgio V Scagliotti, David P Carbone, Hugo J W L Aerts, Dara L Aisner, Jonas Bergh,[...]. J Thorac Oncol 2018
92
9

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, Jose Luis Gonzáles-Larriba, Tomasz Grodzki, Jose Rodrigues Pereira, Alain Le Groumellec, Vito Lorusso,[...]. Lancet Oncol 2006
9

Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Daniel C Betticher, Shu-Fang Hsu Schmitz, Martin Tötsch, Eva Hansen, Christine Joss, Christian von Briel, Ralph A Schmid, Miklos Pless, James Habicht, Arnaud D Roth,[...]. J Clin Oncol 2003
316
9

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Guillaume Mouillet, Elisabeth Monnet, Bernard Milleron, Marc Puyraveau, Elisabeth Quoix, Philippe David, Alain Ducoloné, Olivier Molinier, Gérard Zalcman, Alain Depierre,[...]. J Thorac Oncol 2012
72
12

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P E Postmus, K M Kerr, M Oudkerk, S Senan, D A Waller, J Vansteenkiste, C Escriu, S Peters. Ann Oncol 2017
817
8

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry J Conter, Hans-Georg Kopp, Davey Daniel, Steven McCune, Tarek Mekhail,[...]. Lancet Oncol 2019
669
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.